Justin Michael Jenson

Title: The Innovative Contributions of Justin Michael Jenson

Introduction

Justin Michael Jenson is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative research and development of peptides. With a total of 2 patents, Jenson's work focuses on targeting specific proteins involved in cancer progression.

Latest Patents

Jenson's latest patents include groundbreaking work on peptides selective for Bcl-2 family proteins. These peptides are designed to selectively target combinations of Mcl-1, Bfl-1, and Bcl-xL. The compositions containing these polypeptides are intended for use in cancer treatment, providing a method of administering these peptides to subjects. Another significant patent involves selective Bfl-1 peptides, which are compounds that bind to Bfl-1. Similar to his previous work, these peptides are also aimed at treating cancer by administering them to subjects.

Career Highlights

Throughout his career, Jenson has worked with prestigious institutions such as the Massachusetts Institute of Technology and Dartmouth College. His research has contributed to advancements in understanding and treating cancer, showcasing his commitment to improving patient outcomes.

Collaborations

Some of Jenson's notable coworkers include Amy E. Keating and Vincent Xue. Their collaborative efforts have further enhanced the impact of his research in the scientific community.

Conclusion

Justin Michael Jenson's innovative work in developing cancer-targeting peptides highlights his significant contributions to medical research. His patents and collaborations reflect a dedication to advancing cancer treatment methodologies.